1. Home
  2. ANL vs BDSX Comparison

ANL vs BDSX Comparison

Compare ANL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.38

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.85

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
BDSX
Founded
2004
2005
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Precision Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.0M
53.0M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
ANL
BDSX
Price
$1.38
$7.85
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
28.5K
63.1K
Earning Date
04-20-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.29
52 Week Low
$0.88
$3.44
52 Week High
$2.99
$32.20

Technical Indicators

Market Signals
Indicator
ANL
BDSX
Relative Strength Index (RSI) 51.04 52.12
Support Level $0.88 $7.77
Resistance Level $1.59 $8.38
Average True Range (ATR) 0.18 0.57
MACD 0.00 -0.01
Stochastic Oscillator 70.48 60.38

Price Performance

Historical Comparison
ANL
BDSX

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: